Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aclaris Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACRS
Nasdaq
8731
https://www.aclaristx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aclaris Therapeutics Inc
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
- Apr 23rd, 2024 12:00 pm
Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
- Apr 11th, 2024 2:12 pm
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
- Apr 5th, 2024 1:40 pm
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
- Mar 20th, 2024 1:40 pm
Aclaris (ACRS) Upgraded to Buy: Here's Why
- Mar 4th, 2024 5:00 pm
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
- Mar 4th, 2024 2:40 pm
Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 1st, 2024 12:29 pm
Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%
- Feb 29th, 2024 10:39 am
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
- Feb 27th, 2024 2:35 pm
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
- Feb 27th, 2024 12:00 pm
Can Aclaris Therapeutics (NASDAQ:ACRS) Afford To Invest In Growth?
- Feb 27th, 2024 11:51 am
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
- Feb 20th, 2024 3:00 pm
Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
- Feb 15th, 2024 3:00 pm
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
- Jan 17th, 2024 4:14 pm
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
- Jan 16th, 2024 12:00 pm
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
- Jan 10th, 2024 12:00 pm
Aclaris Therapeutics Provides Corporate Update
- Dec 19th, 2023 9:01 pm
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
- Dec 5th, 2023 9:01 pm
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Dec 4th, 2023 2:35 pm
Down -84.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Aclaris (ACRS)
- Nov 16th, 2023 2:35 pm
Scroll